arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

BriaCell Therapeutics Corp.

BCTX

$3.65 ▲ +0.19 (+5.49%) at close

6 Visible periods

20 Metrics

Absolute Benchmarks

Price Chart

Health

Fair

Neutral Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, BriaCell Therapeutics Corp. shows solid but mixed fundamentals. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $1.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC None

FCF / Share $-66.58 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-26.31M

↓ -449.1% —

FCF / Share Free cash flow per share

$-66.58

↑ +70.3% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
EPS Growth YoY (%)	-42.4% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-3260.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	24.9% Good Good Year-over-year change in earnings per share Optimal: > 10%	43.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-449.1% Weak ↓ Weak Declining Year-over-year change in net income	76.4% Excellent ↑ Excellent Improving Year-over-year change in net income	24.4% Good Good Year-over-year change in net income	-94.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	70.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-14641.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-88.7% Weak Weak Year-over-year change in free cash flow	53.0% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	1.07x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	5.13x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	1.17x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.56x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Return on Invested Capital (%)	—	—	—	-148.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-25.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-125.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-567.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-85.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-35.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	—	-259.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1832%)	-49.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-433%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Interest Coverage (x)	—	—	—	-15616.90x Weak Weak Operating income divided by interest expense Optimal: > 5x	-88.81x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-10.49M	$-862.09K	$-21.25M	$-41.04M	$-57.27M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-62.19	$-43.68	$-1.30	$-1.73	$-3.06	—
Free Cash Flow per Share (USD)	$-66.58	$-224.09	$-1.52	$-0.81	$-1.71	—
Book Value per Share (USD)	—	—	—	$0.67	$1.81	—
Tangible Book Value per Share (USD)	—	—	—	$0.67	$1.81	—
Basic Weighted Avg Shares (shares)	423,114	109,699	15.62M	15.49M	4.52M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Working Capital (USD)	$15.95M	$-3.81M	$25.15M	$41.41M	$57.24M	—
Total Equity (USD)	—	—	—	$10.33M	$27.67M	$-2.74M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Jul 31, 2025 10-K ↗	FY 2024 Jul 31, 2024 10-K ↗	FY 2023 Jul 31, 2023 10-K ↗	FY 2022 Jul 31, 2022 10-K ↗	FY 2021 Jul 31, 2021 10-K ↗	FY 2020 Jul 31, 2020 10-K ↗
Depreciation Expense (USD)	$91.36K	$68.63K	—	$15.27K	$15.26K	—
Net Income, GAAP (USD)	$-26.31M	$-4.79M	$-20.30M	$-26.84M	$-13.82M	—
Operating Cash Flow (USD)	$-28.17M	$-24.13M	$-23.74M	$-12.48M	$-7.75M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 21 quarters

BriaCell Therapeutics Corp.

Analytical Summary

6-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare BCTX with peers